Effect of carbon fiber reinforcement on dimensional variations of 3D printed polyamide-6 composites: A simulation study.

Due to material design and fabrication flexibility, additive manufacturing (AM) or 3D printing (3DP) processes and polymer composites have paved their way into several industrial sectors. The quality of 3D printed polymer composites is highly dependent on the reinforcement content of polymers and 3DP process parameters. Several experimental studies are performed to optimize the reinforcement contents and process parameters; however, exploring the numerical modeling and simulation techniques is vital to lower the research and development costs. In the study, the numerical simulations for the 3DP process were performed using Digimat® software for carbon fiber-reinforced polyamide-6 (PA6) composites fabricated via the fused filament fabrication (FFF) process to evaluate the effect of reinforcement content on deflections, warpages, and process-induced residual stresses. The FFF process simulations were performed to fabricate tensile testing coupons with pure PA6 and 10%-28% CF-reinforced PA6 composites. A significant impact of CF-reinforcement was observed on the deflections, warpages, and residual stresses. The maximum displacement of 4.518 mm and critical warpage of 3.012 was observed for pure PA6 material. However, with the addition of CF reinforcement, a maximum deflection of 3.369 mm and critical warpage of 2.246 was achieved for PA6 reinforced with 28% CF (PA6-CF28). The improved 3D printed specimen quality was acquired at the cost of increased residual stresses of 14.53 MPa compared to 11.75 MPa in pure PA6 specimen. The CF reinforcement significantly improved the 3DP manufacturing performance of PA6/CF composites, reducing deflections and warpages.

Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.

OBJECTIVES: We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopeptidase and ACE with omapatrilat may represent a new treatment strategy in CHF. METHODS: Three hundred and sixty-nine patients with symptomatic heart failure were randomized to double-blind treatment with omapatrilat (first 190 patients: 2.5 mg, 5 mg or 10 mg; last 179 patients: 2.5 mg, 20 mg or 40 mg once daily) for 12 weeks. RESULTS: Acutely, the 10 mg, 20 mg and 40 mg doses of omapatrilat produced greater reductions in pulmonary capillary wedge pressure (PCWP), systolic blood pressure (SBP) and systemic vascular resistance compared with 2.5 mg. Higher doses were associated with greater increases in vasodilator and natriuretic peptides, in addition to ACE inhibition. After 12 weeks, omapatrilat 20 mg and 40 mg showed greater falls from baseline in PCWP (40 mg: 0 h to 12 h average change -7.3 +/- 0.8 mm Hg) and SBP (40 mg: -11.7 +/- 1.7 mm Hg) than 2.5 mg (both p < 0.01 vs. 2.5 mg). The incidence of adverse experiences and patient withdrawal were similar in all groups. CONCLUSIONS: In CHF, the acute hemodynamic benefit seen with higher doses of omapatrilat was associated with increases in plasma vasodilator and natriuretic peptide levels in addition to ACE inhibition. After 12 weeks, the hemodynamic benefit was maintained. Omapatrilat may be a promising new agent in CHF.

Continual recordings of cardiac sympathetic nerve activity in conscious sheep.

Cardiac sympathetic nerve activity (CSNA) is of major importance in the etiology of heart disease but is impossible to measure directly in humans. Ovine and human cardiovascular systems are similar; therefore, we have developed a method for the daily recording of CSNA in conscious sheep. After thoracotomy, electrodes were glued into the left thoracic cardiac nerve and CSNA, blood pressure (BP), and heart rate were recorded daily. Satisfactory recordings > or =7 days of CSNA were obtained in 11 of 28 sheep (40%), mean recording time 10.6 days, range 7-47. During the first week, CSNA decreased gradually from 78 +/- 8 at baseline to 60 +/- 7 bursts/min on day 5 (P = 0.02) or from 76 +/- 9 to 57 +/- 7 bursts/100 beats on day 7 (P = 0.04). Similarly, BP decreased from 103 +/- 4 to 94 +/- 4 mmHg (P = 0.03). Low-frequency heart rate variability decreased from 0.12 +/- 0.02 to 0.06 +/- 0.02 ms(2) on day 6 (P = 0.004) but was not correlated to CSNA. In conclusion, CSNA that can be continually recorded in conscious sheep decreases during the first week postsurgery and, thereafter, stabilizes. This model should provide valuable insights in future investigations of cardiac disease.